2:02 PM
 | 
Sep 13, 2018
 |  BC Extra  |  Company News

FDA approves AZ's hairy cell leukemia drug

FDA approved Lumoxiti moxetumomab pasudotox-tdfk from AstraZeneca plc (LSE:AZN; NYSE:AZN) to treat relapsed or refractory hairy cell leukemia...

Read the full 67 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >